β-Glucan, a “Specific” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)

J Immunol September 15, 1999, 163 (6) 3045-3052;Yan J Immunol 1999 — Article shows that beta glucan enhances tumor targeting by immune cells when used with certain antibodies. Article also describes beta glucan’s role in  (modifying) cancer tumor cells with an iC3b...